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Abstract Interesting, recent studies have suggested a possibility 
that transcriptional factor N F - K B may play a functional role in 
the survival of mouse osteoclasts. However, it has not been 
known whether N F - K B is involved in apoptosis of and bone 
resorption by mature osteoclasts. Thus, using N F - K B inhibitors, 
we examined the functional role of N F - K B in the induction of 
apoptosis in rabbit mature osteoclasts. PDTC, a potent inhibitor 
of N F - K B , stimulated markedly apoptosis of the osteoclasts and 
inhibited bone resorption by these cells. These effects also was 
observed when three other inhibitors of N F - K B were used. And a 
gel mobility shift assay showed that PDTC also inhibited N F - K B 
binding to its consensus sequence in the cells. These results 
suggest a regulatory role for N F - K B in apoptosis in and bone 
resorption by rabbit mature osteoclasts. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Osteoclasts play a crucial role in bone remodeling, because 
these cells are the predominant type involved in bone resorp-
tion. The osteoclastic cell functions are regulated negatively or 
positively by several kinds of cytokine such as growth factors, 
vitamins, and inflammatory factors [1,2]. Although these fac-
tors may regulate the functions of the osteoclasts via some 
transcriptional factor(s), the precise role of such a factor(s) 
in osteoclastic function has not been demonstrated in detail. 
Recent studies [3,4] have suggested the possible involvement 
of N F - K B in osteoclast activation. Therefore, we carried out 
experiments to examine the possible role of this transcription-
al factor in apoptosis in and bone resorption by rabbit mature 
osteoclasts. 
In the present study, using several inhibitors of N F - K B 
activity, we examined the functional role of N F - K B in apop-
tosis and bone resorption by rabbit osteoclasts and demon-
strated that the N F - K B inhibitors clearly inhibited bone re-
sorption in parallel with their stimulation of apoptosis in the 
cells. 
2. Materials and methods 
2.1. Preparation of rabbit osteoclasts 
Rabbit osteoclasts were prepared and isolated by a slight modifica-
tion of the method described by Tezuka et al. [5]. Briefly, rabbit 
femoral bones were minced in a-MEM (Flow Lab., McLean, VA), 
and then the cell suspension was overlaid on a Percoll (Pharmacia 
Japan, Tokyo, Japan) solution having a specific gravity of 1.07. 
*Corresponding author. Fax: 81-492-85-1035. 
Thereafter, the cells were centrifuged for 20 min at 350 Xg. The cells 
having the specific gravity 1.07 were harvested and washed with a-
MEM, and then seeded into 30-mm plastic dishes (Falcon, Becton 
Dickinson Labware, Oxnard, CA) or Lab-Tek chambers (Nunc, Na-
perville, IL). 5 h later, the purified osteoclasts were prepared by re-
moving stromal cells with 0.002% EDTA and 0.02% pronase, and 
used in subsequent experiments. 
2.2. NF-KB inhibitors 
Pyrrolidine dithiocarbamate (PDTC), A'-tosyl-L-phenylalanine 
chloromethyl keton (TPCK), and gliotoxin were purchased from Sig-
ma Chemical Co. (St. Louis, MO). Curcumin was obtained from 
Nakarai Tesque (Kyoto, Japan). The characterizations of each inhib-
itor for N F - K B were made previously [6-9]. 
2.3. Cytochemical staining 
Morphological changes in the nuclear chromatin of apoptotic cells 
were detected by staining with Hoechst 33258 (Sigma) as described 
previously [10]. After treatment with each inhibitor, cells were fixed 
with 3% paraformaldehyde for 10 min, washed in PBS, and stained 
with Hoechst 33258 (16 u.g/ml) for 15 min. Thereafter, the cells were 
observed by fluorescence microscopy (Olympus BX60; Tokyo, Japan). 
More than 200 osteoclasts were scored for the incidence of apoptotic 
chromatin changes. The results were expressed as the mean ± S.D. of 
triplicate cultures. 
2.4. Agarose gel electrophoresis for DNA fragmentation 
To assess DNA fragmentation, we prepared DNA from the osteo-
clasts and analyzed it by a slight modification of the electrophoretic 
method described previously [11]. The osteoclasts were treated or not 
with each inhibitor and then lysed by incubation in digestion buffer 
(150 mM NaCl, 25 mM EDTA, 100 ug/ml proteinase K, and 0.2% 
SDS). The DNA was extracted with phenol/chloroform, precipitated 
with 0.5 M NaCl and ethanol, and electrophoresed on 3% agarose gel 
containing ethidium bromide, and then the DNA fragments were 
visualized under UV light. 
2.5. Bone resorption assay 
Bone resorption assay was determined by counting bone resorption 
pits as described previously [12], tartrate-resistant acid phosphatase 
(TRAP)-positive cells (1 X103 cells) in a cell suspension of rabbit 
femoral bones were incubated for 60 min on a dentin slice (4X4 
mm) in each well of a 24-well flat-type Falcon plastic plate containing 
a-MEM supplemented with 10% fetal bovine serum (Flow Labs, 
McLean, VA). Then, the nonadherent cells were removed by washing 
with a-MEM. Thereafter, the cells on the dentin slices were incubated 
for the selected times in a-MEM with or without each inhibitor. The 
bone resorption pits were counted, and the results were expressed as 
the mean ± S.D. of quadruplicate cultures. 
2.6. Gel mobility shift assay 
Preparation of cell extracts and the assay were carried out as de-
scribed previously [13,14]. Briefly, binding reactions were performed 
with 15 ug of the sample protein in a mixture of 2 mM Tris (pH 7.5), 
8 mM NaCl, 0.2 mM EDTA, 0.8% (v/v) glycerol, 0.2 mM DTT, and 
20 000 cpm of a 32P-labeled N F - K B oligonucleotide containing a tan-
dem repeat of the consensus sequence for the binding site for N F - K B , 
-GGGGACTTTCC-, which was end labeled by the T4 polynucleotide 
kinase-[y-32P]ATP method. Unlabeled double-stranded oligonucleo-
tide was used as a competitor. DNA-protein complexes were electro-
phoresed on native 5% polyacrylamide gels in 0.25 X TBE buffer (22 
mM Tris (pH 8.0), 22 mM boric acid, 0.6 mM EDTA). Gels were 
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Fig. 1. PDTC stimulates apoptosis of rabbit mature osteoclasts. (A-D): TRAP-positive cells (1X104 cells) in a femoral bone cell suspension 
were inoculated into each well of a Lab-Tek chamber, and then isolated osteoclasts prepared as described in Section 2 were treated (B, D) or 
not (A, C) with PDTC at 10 uM. After 12 h, the cells were fixed. Phase-contrast photomicrographs and corresponding fluorescence photomi-
crographs taken after nuclear staining with Hoechst 33258 are shown. (E) Osteoclasts prepared as described above were treated or not with 
PDTC at 10 uM, and lysed in digestion buffer 12 h later. Then, their genomic DNA was extracted and subjected to agarose gel 
electrophoresis. <|)X174 RF DNAJHaelll Fragments were used as molecular weight markers (left lane). 
vacuumed, dried, and exposed for 18 h to Kodak X-ray film at 
-70°C. 
3. Results 
3.1. PDTC stimulates apoptosis of rabbit osteoclasts 
Many studies [11,15-17] have demonstrated that N F - K B is 
associated with apoptosis in several kinds of cells. Therefore, 
firstly, using PDTC, a potent inhibitor of N F - K B , we looked 
by phase contrast and fluorescence microscopy for apoptotic 
chromatin changes in PDTC-untreated or -treated osteoclasts. 
As shown in Fig. 1 (B and D), we observed that PDTC-
treated multinucleate osteoclasts exhibited morphological 
changes indicative of apoptosis, including chromatin conden-
sation and nuclear fragmentation. However, such morpholog-
ical changes were not observed in the control, untreated os-
teoclasts (Fig. 1A and C). We also analyzed DNA from these 
cells by agarose gel electrophoresis for evidence of fragmenta-
tion (Fig. IE). By 12 h of treatment with PDTC, a substantial 
DNA ladder was detected in the treated cells. 
Fig. 2 shows that PDTC at 10 uM stimulated apoptosis in 
the osteoclasts in a treatment time-dependent fashion. This 
apoptotic effect was also observed with 1 uM PDTC (data 
not shown). These results suggest that N F - K B is an important 
transcriptional factor in the regulation of apoptosis of rabbit 
mature osteoclasts. 
3.2. PDTC inhibits NF-KB factor binding in rabbit osteoclasts 
Next, we examined by the gel mobility shift assay whether 
the presence of N F - K B could be detected in the osteoclasts, 
and if so, also whether N F - K B binding activity in the cells is 
inhibited by PDTC. As shown in Fig. 3, although the binding 
of nuclear extracts from control osteoclasts to the consensus 
sequence of the binding site for N F - K B was observed, the N F -
KB binding clearly disappeared by treatment with PDTC at 10 
uM. Since the N F - K B binding was completely inhibited by its 
competitor, these results suggest that PDTC inhibits the con-
stitutive appearance of N F - K B in rabbit osteoclasts. 
3.3. PDTC inhibits osteoclastic bone resorption 
The PDTC stimulation of osteoclast apoptosis suggested to 
us the possibility that PDTC treatment may also cause inhib-
ition of bone resorption by the osteoclasts. Therefore, we 
examined this point. As shown in Fig. 4, PDTC treatment 
inhibited the bone resorption of the osteoclasts in a treatment 
time-dependent manner. 
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Fig. 2. Kinetics of PDTC stimulation of apoptosis of rabbit mature 
osteoclasts. Isolated osteoclasts prepared as described in Section 2 
were treated or not with PDTC at 10 uM in cc-MEM. More than 
200 osteoclasts were scored for the incidence of apoptotic chromatin 
changes. Three identical experiments independently performed gave 
similar results. 
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3.4. Effect of several NF-KB inhibitors on apoptosis in and bone 
resorption by osteoclasts 
As shown above, N F - K B may play regulatory role in bone 
resorption by osteoclasts through regulation of apoptosis of 
its cells. Therefore, to confirm this possibility, we also exam-
ined several additional inhibitors of N F - K B for their effect on 
apoptosis and bone resorption of rabbit osteoclasts. As shown 
in Fig. 5 (A and B), we observed a significant increase in the 
number of apoptotic cells, which became apparent 12 h after 
the addition of each inhibitor. Also, each inhibitor dramati-
cally inhibited osteoclastic bone resorption of the osteoclasts. 
And the inhibitory action of each reagent was dose dependent 
(data not shown). 
4. Discussion 
Transcriptional factor N F - K B activates the transcription of 
certain genes via its binding to specific DNA consensus se-
quences on these genes. The involvement of N F - K B in apop-
tosis has been suggested previously [11,15-17], and more re-
cent studies [18-21] have suggested that activation of N F - K B 
is able to protect against cell killing by apoptotic stimuli in 
several kinds of cells. However, the actual role of this tran-
scriptional factor in apoptosis in and bone resorption by ma-
ture osteoclasts has not been demonstrated in detail. 
We observed here the stimulatory action of PDTC, a N F -
KB inhibitor, toward rabbit osteoclast apoptosis. Interestingly, 
this chemical also clearly inhibited osteoclastic bone resorp-
tion. Furthermore, we showed that three other N F - K B inhib-
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Fig. 4. Inhibitory effect of PDTC on osteoclast-mediated bone re-
sorption. TRAP-positive cells (1 X 103 cells) in a femoral bone cell 
suspension were inoculated onto each of several dentin slices and 
rinsed 1 h later to remove the nonadherent stromal cells. Then the 
cells were treated or not with PDTC at 10 uM. After the selected 
times, the resorption pit number was counted. The results are ex-
pressed as the mean ± S.D. of quadruplicate cultures. Three identical 
experiments independently performed gave similar results. 
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Fig. 3. PDTC inhibits NF-KB binding in rabbit mature osteoclasts. 
Osteoclasts were treated or not with PDTC at 10 uM; and after 6 h, 
the nuclear proteins were prepared. Gel mobility shift assay was 
performed with 32P-labeled oligonucleotide or unlabeled oligonucleo-
tide as a competitor containing the NF-KB consensus sequence in 
the presence of the nuclear proteins. An identical experiment inde-
pendently performed gave similar results. 
itors, gliotoxin, curcumin, and TPCK, exhibited the same 
mode of action as PDTC toward rabbit osteoclasts. To our 
knowledge, this is the first observation that N F - K B is a potent 
regulator of apoptosis in and bone resorption by mature os-
teoclasts. 
Recent studies [22,23] have shown that N F - K B in mouse 
osteoclasts is stimulated by interleukin-1 (IL-1). On the other 
hand, although we showed that the constitutive binding of 
N F - K B to its consensus sequence in rabbit osteoclasts was 
inhibited by PDTC with high specificity, this inhibition of 
N F - K B binding does not directly prove the functional role 
of this transcriptional factor in bone resorption by osteoclasts 
in relation to stimulation of apoptosis in these cells. However, 
N F - K B may be an important transcriptional factor in these 
processes in view of the fact that the other three N F - K B in-
hibitors tested also showed the same mode of action as 
PDTC. 
As described above, since IL-1 may involved in the survival 
of osteoclast-like cells and since this cytokine is able to induce 
the appearance of N F - K B in the cells, these facts together with 
our present study, results suggest that N F - K B plays a func-
tional role in the survival of osteoclasts. 
In conclusion, we showed herein that N F - K B inhibition 
potently stimulates osteoclast apoptosis and inhibits bone re-
sorption by these cells. Stimulation of osteoclast apoptosis 
may be proposed as a useful strategy for the therapy of dis-
eases involving increased osteoclastic bone resorption. In fur-
ther experiments, it will be very important for us to analyze 
the molecular mechanisms for the precise action of N F - K B in 
survival or apoptosis of osteoclasts. 
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Fig. 5. Other inhibitors also induce apoptosis of osteoclasts and block osteoclastic bone resorption. (A) Isolated osteoclasts prepared as de-
scribed in Section 2 were treated or not with 10 uM curcumin, 10 uM TPCK, or 1 ug/ml gliotoxin in a-MEM. After a 12-h incubation, more 
than 200 osteoclastic cells were scored for the incidence of apoptotic chromatin changes. (B) TRAP-positive cells (1 X 103 cells) were prepared 
as described in Section 2. Then, the cells were treated or not with curcumin at 10 uM, TPCK at 10 uM, or gliotoxin at 1 ug/ml in a-MEM. 
After an 18-h incubation, the resorption pit number was counted. The results are expressed as the mean±S.D. of quadruplicate cultures. Three 
identical experiments independently performed gave similar results. 
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